{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:04:54Z","timestamp":1794027894904,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03263-w","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:27:11Z","timestamp":1669958831000},"page":"430-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Statin intolerance management: a systematic review"],"prefix":"10.1007","volume":"79","author":[{"given":"Alejandra","family":"Meza-Contreras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Wenczenovicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Ruiz-Arellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa A. Kinzelman","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mogollon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-2898","authenticated-orcid":false,"given":"Victor M.","family":"Montori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"3263_CR1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"C.W. Tsao, A.W. Aday, Z.I. Almarzooq, A. Alonso, A.Z. Beaton et al. Heart disease and stroke statistics 2022 update: a report from the American Heart Association. Circulation 145, e153\u2013e639 (2022)","journal-title":"Circulation"},{"key":"3263_CR2","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"D.K. Arnett, R.S. Blumenthal, M.A. Albert, A.B. Buroker, Z.D. Goldberger et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596\u2013e646 (2019)","journal-title":"Circulation"},{"key":"3263_CR3","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"S.M. Grundy, N.J. Stone, A.L. Bailey, C. Beam, K.K. Birtcher et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, e1082\u2013e1143 (2019)","journal-title":"Circulation"},{"key":"3263_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"M.K. Cheeley, J.J. Saseen, A. Agarwala, S. Ravilla, N. Ciffone et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J. Clin. Lipido. 16, 361\u2013375 (2022)","journal-title":"J. Clin. Lipido."},{"key":"3263_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1210\/jc.2009-2689","volume":"95","author":"RH Eckel","year":"2010","unstructured":"R.H. Eckel, Approach to the patient who is intolerant of statin therapy. J. Clin. Endocrinol. Metab. 95, 2015\u20132022 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3263_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5551\/jat.RV17030","volume":"26","author":"R Alonso","year":"2019","unstructured":"R. Alonso, A. Cuevas, A. Cafferata, Diagnosis and Management of Statin Intolerance. J. Atheroscler. Thromb. 26, 207\u2013215 (2019)","journal-title":"J. Atheroscler. Thromb."},{"key":"3263_CR7","doi-asserted-by":"publisher","first-page":"e2136802","DOI":"10.1001\/jamanetworkopen.2021.36802","volume":"4","author":"W Thompson","year":"2021","unstructured":"W. Thompson, L. Morin, D.E. Jarbol, J.H. Andersen, M.T. Ernst et al. Statin discontinuation and cardiovascular events among older people in Denmark. JAMA Netw. Open 4, e2136802 (2021)","journal-title":"JAMA Netw. Open"},{"key":"3263_CR8","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Bytyci","year":"2022","unstructured":"I. Bytyci, P.E. Penson, D.P. Mikhailidis, N.D. Wong, A.V. Hernandez et al. Prevalence of statin intolerance: a meta-analysis. Eur. Heart J. 43, 3213\u20133223 (2022)","journal-title":"Eur. Heart J."},{"key":"3263_CR9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","volume":"400","author":"Cholesterol Treatment Trialists C","year":"2022","unstructured":"Cholesterol Treatment Trialists C, Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 400, 832\u2013845 (2022)","journal-title":"Lancet"},{"key":"3263_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1161\/CIRCOUTCOMES.111.000039","volume":"6","author":"JP Brito","year":"2013","unstructured":"J.P. Brito, V.M. Montori, Reinitiation of statins after statin-associated musculoskeletal symptoms: a patient-centered approach. Circ. Cardiovasc Qual. Outcomes 6, 243\u2013247 (2013)","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"3263_CR11","unstructured":"A. Meza, V. Montori, R. Mogollon, A. Meza, C. Wenczenovicz, et al., (2022) Statin intolerance management: A systematic review. CRD42022318746"},{"key":"3263_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021)","journal-title":"BMJ"},{"key":"3263_CR13","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/jcsm.12960","volume":"13","author":"PE Penson","year":"2022","unstructured":"P.E. Penson, E. Bruckert, D. Marais, Z. Reiner, M. Pirro et al. Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J. Cachexia Sarcopenia Muscle 13, 1596\u20131622 (2022)","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"3263_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2174\/157016111904210216104403","volume":"19","author":"Z Fras","year":"2021","unstructured":"Z. Fras, Current choice for LDL-C Lowering in High-Risk CVD patients intolerant to statins. Curr. Vasc. Pharm. 19, 398\u2013402 (2021)","journal-title":"Curr. Vasc. Pharm."},{"key":"3263_CR15","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.nurpra.2021.06.005","volume":"17","author":"D Lempp","year":"2021","unstructured":"D. Lempp, An evidence-based guideline for treating dyslipidemia in statin-intolerant patients. J. Nurse Practitioners 17, 910\u2013915 (2021)","journal-title":"J. Nurse Practitioners"},{"key":"3263_CR16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"E.S. Stroes, P.D. Thompson, A. Corsini, G.D. Vladutiu, F.J. Raal et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012\u20131022 (2015)","journal-title":"Eur. Heart J."},{"key":"3263_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"M. Banach, M. Rizzo, P.P. Toth, M. Farnier, M.H. Davidson et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch. Med Sci. 11, 1\u201323 (2015)","journal-title":"Arch. Med Sci."},{"key":"3263_CR18","doi-asserted-by":"publisher","first-page":"D3","DOI":"10.1093\/eurheartj\/sux029","volume":"19","author":"MM Gulizia","year":"2017","unstructured":"M.M. Gulizia, F. Colivicchi, G. Ricciardi, S. Giampaoli, A.P. Maggioni et al. ANMCO\/ISS\/AMD\/ANCE\/ARCA\/FADOI\/GICR-IACPR\/SICI-GISE\/SIBioC\/SIC\/SICOA\/SID\/SIF\/SIMEU\/SIMG\/SIMI\/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic\u2013therapeutic pathway in Italy. Eur. Heart J. Suppl. 19, D3\u2013D54 (2017)","journal-title":"Eur. Heart J. Suppl."},{"key":"3263_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.amjmed.2021.09.014","volume":"135","author":"SM Grundy","year":"2022","unstructured":"S.M. Grundy, G.L. Vega, Statin intolerance and noncompliance: an empiric approach. Am. J. Med 135, 318\u2013323 (2022)","journal-title":"Am. J. Med"},{"key":"3263_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","volume":"18","author":"PP Toth","year":"2018","unstructured":"P.P. Toth, A.M. Patti, R.V. Giglio, D. Nikolic, G. Castellino et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am. J. Cardiovasc Drugs 18, 157\u2013173 (2018)","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"3263_CR21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jfma.2018.11.017","volume":"118","author":"SC Chien","year":"2019","unstructured":"S.C. Chien, P.S. Chen, Y.H. Huang, S.C. Tang, Y.H. Li et al. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. J. Formos. Med Assoc. 118, 1385\u20131392 (2019)","journal-title":"J. Formos. Med Assoc."},{"key":"3263_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/17425255.2020.1802426","volume":"16","author":"JJ Li","year":"2020","unstructured":"J.J. Li, H.H. Liu, N.Q. Wu, K.K. Yeo, K. Tan et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin. Drug Metab. Toxicol. 16, 837\u2013851 (2020)","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"3263_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.hjc.2019.09.001","volume":"61","author":"LS Rallidis","year":"2020","unstructured":"L.S. Rallidis, A practical algorithm for the management of patients with statin-associated muscle symptoms. Hellenic J. Cardiol. 61, 137\u2013140 (2020)","journal-title":"Hellenic J. Cardiol."},{"key":"3263_CR24","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"D.M. Lloyd-Jones, P.B. Morris, C.M. Ballantyne, K.K. Birtcher, D.D. Daly Jr. et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J. Am. Coll. Cardiol. 70, 1785\u20131822 (2017)","journal-title":"J. Am. Coll. Cardiol."},{"key":"3263_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1567-5688(17)30024-7","volume":"26","author":"U Laufs","year":"2017","unstructured":"U. Laufs, K.J. Filipiak, I. Gouni-Berthold, A.L. Catapano; group Sew, Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler. Suppl. 26, 45\u201355 (2017)","journal-title":"Atheroscler. Suppl."},{"key":"3263_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/imj.14429","volume":"49","author":"A Sivashanmugarajah","year":"2019","unstructured":"A. Sivashanmugarajah, J. Fulcher, D. Sullivan, M. Elam, A. Jenkins et al. Suggested clinical approach for the diagnosis and management of \u2018statin intolerance\u2019 with an emphasis on muscle-related side-effects. Intern Med. J. 49, 1081\u20131091 (2019)","journal-title":"Intern Med. J."},{"key":"3263_CR27","first-page":"2245","volume":"38","author":"U Landmesser","year":"2017","unstructured":"U. Landmesser, M.J. Chapman, M. Farnier, B. Gencer, S. Gielen et al. European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur. Heart J. 38, 2245\u20132255 (2017)","journal-title":"Eur. Heart J."},{"key":"3263_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","volume":"26","author":"Y Handelsman","year":"2020","unstructured":"Y. Handelsman, P.S. Jellinger, C.K. Guerin, Z.T. Bloomgarden, E.A. Brinton et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm \u2013 2020 executive summary. Endocr. Pract. 26, 1196\u20131224 (2020)","journal-title":"Endocr. Pract."},{"key":"3263_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","volume":"70","author":"RS Rosenson","year":"2017","unstructured":"R.S. Rosenson, S. Baker, M. Banach, K.M. Borow, L.T. Braun et al. Optimizing cholesterol treatment in patients with muscle complaints. J. Am. Coll. Cardiol. 70, 1290\u20131301 (2017)","journal-title":"J. Am. Coll. Cardiol."},{"key":"3263_CR30","doi-asserted-by":"crossref","unstructured":"A.R. Barry, J.E. Beach, G.J. Pearson. Prevention and management of statin adverse effects: A practical approach for pharmacists. Can. Pharm. J. 151, 179\u2013188 (2018)","DOI":"10.1177\/1715163518768534"},{"key":"3263_CR31","doi-asserted-by":"publisher","first-page":"519S","DOI":"10.1093\/advances\/nmy010","volume":"9","author":"AL Zaleski","year":"2018","unstructured":"A.L. Zaleski, B.A. Taylor, P.D. Thompson, Coenzyme Q10 as treatment for statin-associated muscle symptoms-a good idea, but. Adv. Nutr. 9, 519S\u2013523S (2018)","journal-title":"Adv. Nutr."},{"key":"3263_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","volume":"31","author":"RS Rosenson","year":"2017","unstructured":"R.S. Rosenson, K. Miller, M. Bayliss, R.J. Sanchez, M.T. Baccara-Dinet et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 31, 179\u2013186 (2017)","journal-title":"Cardiovasc Drugs Ther."},{"key":"3263_CR33","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"C.B. Newman, D. Preiss, J.A. Tobert, T.A. Jacobson, R.L. Page 2nd et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb. Vasc. Biol. 39, e38\u2013e81 (2019)","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"3263_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","volume":"14","author":"A Selva-O\u2019Callaghan","year":"2018","unstructured":"A. Selva-O\u2019Callaghan, M. Alvarado-Cardenas, I. Pinal-Fernandez, E. Trallero-Araguas, J.C. Milisenda et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev. Clin. Immunol. 14, 215\u2013224 (2018)","journal-title":"Expert Rev. Clin. Immunol."},{"key":"3263_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/HCO.0000000000000874","volume":"36","author":"CC Diaconu","year":"2021","unstructured":"C.C. Diaconu, R.A. Iorga, F. Furtunescu, N. Katsiki, A.P. Stoian et al. Statin intolerance: new data and further options for treatment. Curr. Opin. Cardiol. 36, 487\u2013493 (2021)","journal-title":"Curr. Opin. Cardiol."},{"key":"3263_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2017.05.013","volume":"30","author":"S Fischer","year":"2017","unstructured":"S. Fischer, U. Julius, Management of patients with statin intolerance. Atheroscler. Suppl. 30, 33\u201337 (2017)","journal-title":"Atheroscler. Suppl."},{"key":"3263_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s43058-021-00145-6","volume":"2","author":"JL Ridgeway","year":"2021","unstructured":"J.L. Ridgeway, M.E. Branda, D. Gravholt, J.P. Brito, I.G. Hargraves et al. Increasing risk-concordant cardiovascular care in diverse health systems: a mixed methods pragmatic stepped wedge cluster randomized implementation trial of shared decision making (SDM4IP). Implement Sci. Commun. 2, 43 (2021)","journal-title":"Implement Sci. Commun."},{"key":"3263_CR38","unstructured":"Knowledge and Evaluation Research Unit at Mayo Clinic, (2021) Heart Health. A CV Prevention Choice Tool."},{"key":"3263_CR39","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.pec.2019.07.020","volume":"102","author":"IG Hargraves","year":"2019","unstructured":"I.G. Hargraves, V.M. Montori, J.P. Brito, M. Kunneman, K. Shaw et al. Purposeful SDM: A problem-based approach to caring for patients with shared decision making. Patient Educ. Couns. 102, 1786\u20131792 (2019)","journal-title":"Patient Educ. Couns."},{"key":"3263_CR40","doi-asserted-by":"crossref","unstructured":"M. Kunneman, I.P.M. Griffioen, N.H.M. Labrie, M. Kristiansen, V.M. Montori, et al., (2021) Making care fit manifesto. BMJ Evid Based Med.","DOI":"10.1136\/bmjebm-2021-111871"},{"key":"3263_CR41","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1016\/j.jaip.2021.09.035","volume":"9","author":"DK Chu","year":"2021","unstructured":"D.K. Chu, D.B.K. Golden, G.H. Guyatt, Translating evidence to optimize patient care using GRADE. J. Allergy Clin. Immunol. Pr. 9, 4221\u20134230 (2021)","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"3263_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.revmed.2020.11.007","volume":"42","author":"CM Yelnik","year":"2021","unstructured":"C.M. Yelnik, \u00c9. Bruckert, Hypercholest\u00e9rol\u00e9mie, du d\u00e9pistage au traitement: quelle prise en charge, pour qui et pour quel b\u00e9n\u00e9fice. La Rev. de. M\u00e9decine Interne 42, 707\u2013713 (2021)","journal-title":"La Rev. de. M\u00e9decine Interne"},{"key":"3263_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","volume":"6","author":"H Drexel","year":"2020","unstructured":"H. Drexel, A.J.S. Coats, I. Spoletini, C. Bilato, V. Mollace et al. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. Eur. Heart J. Cardiovasc Pharmacother. 6, 115\u2013121 (2020)","journal-title":"Eur. Heart J. Cardiovasc Pharmacother."},{"key":"3263_CR44","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1556\/650.2018.31192","volume":"159","author":"L Bajnok","year":"2018","unstructured":"L. Bajnok, Newer evidences and recommendations in lipidology. Orv. Hetil. 159, 1303\u20131309 (2018)","journal-title":"Orv. Hetil."},{"key":"3263_CR45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","volume":"15","author":"BA Taylor","year":"2018","unstructured":"B.A. Taylor, P.D. Thompson, Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics 15, 1006\u20131017 (2018)","journal-title":"Neurotherapeutics"},{"key":"3263_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"European Society of Cardiology","year":"2019","unstructured":"European Society of Cardiology, 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 290, 140\u2013205 (2019)","journal-title":"Atherosclerosis"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03263-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T12:23:17Z","timestamp":1678105397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03263-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["3263"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03263-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no financial conflicts of interest. V.M.M. participates in the design, development, implementation, evaluation, and dissemination of shared decision making tools. Neither V.M.M. nor the Knowledge and Evaluation Research receive for-profit funding for this work or derive income from the shared decision making tools that result from it which are placed in the public domain for free use at\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}